Follow-Up To REDUCE Study Shows Low Rate Of Prostate Cancer Diagnosis

Analysis of 2 Years of Additional Data on Dutasteride Treatment Reported in The Journal of Urology® The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news